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Disruptions in mineral metabolism occur already at an early stage of chronic kidney disease 
(CKD) and may eventually lead to a complex of CKD - mineral and bone disorders (CKD-
MBD) characterized by alterations of the mass, turnover rate, mineralization and strength of 
bones, and high risk of vascular calcification, fractures and other complications resulting in 
worse survival. The aim of this thesis was to increase the understanding of some aspects of 
CKD-MBD with special emphasis on clinical and laboratory determinants and implications for 
clinical outcome. 
 
In Study 1, we defined and tested a novel non-surgical, adjustable model of tubulointerstitial 
nephropathy in mice by adding adenine to a casein-based diet and showed that this model could 
induce and maintain a uremic phenotype with decline of renal function and initiation of 
alterations linked to CKD-MBD.   
 
In Study 2, we investigated the impact of classical risk factors for osteoporosis such as age, 
body composition, and nutritional status in end-stage renal disease (ESRD) subjects, and how 
these factors influence the relationship between bone mineral density (BMD) and mortality in 
patients with ESRD. We found that low BMD is associated with low total fat mass, poor 
nutritional status and increased mortality risk in ESRD patients. 
 
In Study 3, we studied determinants of the variability of two bone metabolic markers, fibroblast 
growth factor-23 (FGF23) and intact parathyroid hormone (PTH) in ESRD patients treated by 
peritoneal dialysis, hemodialysis or online hemodiafiltration. We found that baseline vitamin D 
status and serum phosphorous were independent determinants of the longitudinal variation in 
PTH and FGF23, respectively, and that the intra-subject variability of FGF23 was lower than 
the variability of PTH irrespective of dialysis mode.  
 
In Study 4, we analyzed baseline serum insulin-like growth factor 1(IGF-1) concentration and 
the longitudinal changes of IGF-1 over 1-year in CKD stage 5 patients starting on dialysis in 
relation to bone and mineral metabolism parameters including BMD, nutritional status, and 
mortality. We found that IGF-1 associates with markers of mineral and bone metabolism and 
that IGF-1 is a strong independent predictor of mortality risk in CKD stage 5 patients.   
 
